| APULDON
Domperidone
Description:
Domperidone is
dopamine receptor (D2) antagonist which is a selective
peripheral dopamine antagonist at the D2 dopamine
receptor and acts principally at receptor in the chemoreceptor
trigger zone (CTZ) and also at receptors in the stomach. Domperidone
does not readily enter the central nervous system or cross the
blood-brain barrier. Domperidone increases spontaneosus gastric
activity and antagonises dopamine inhibition of gastric emptying.
Domperidone also exerts effects at some points of CNS that do
not possess blood-brain barrier and thus controls emesis. Thus
domperidone acts as an antiemetic and gastroprokinetic agent.
Composition:
Apuldon Tablet:
Each tablet contains Domperidone Maleate BP equivalent to Domperidone
10 mg.
Apuldon Suspension:
Each 5 ml contains Domperidone BP 5 mg.
Apuldon Paediatric
Drops: Each ml contains Domperidone BP 5 mg.
Indications:
1. Stimulation
of gut mobility:
• Non-ulcer dyspepsia
• Esophageal reflux,
reflux esophagitis & gastritis
• Speeding barium
transit in 'follow-through' radioloigical studies.
• Diabetic gastroparesis.
2. Prevention
and symptomatic relief from acute nausea & vomiting in adults
from any cause but specially:
• Cytotoxic therapy
& radiotherapy
• Nausea &
vomiting associated with migraine attacks (in combination with
analgesics)
• L-dopa and bromocriptine
treatment for Parkinsonian patients
3. Functional
dyspepsia.
Dosage &
Administration:
The recommended
oral dose for:
Adults:
10-20 mg every 4-8 hours daily.
Children (2-12
years): 0.2-0.4 mg/kg body weight (0.4-0.8 ml paediatric
drops/10 Kg) every 4-8 hours daily.
Note: Both tablet
& suspension should be taken 15-30 minutes before a meal.
For acute nausea & vomiting maximum period of treatment
is 12 weeks.
Contraindications:
Patients with a
known allergy to Domperidone or Domperidone Maleate or any inactive
ingredient of the product and neonates.
Side-effects:
Apuldon
may produce hyperprolactinemia which may cause galactorrhoea
& breast enlargement. It may rarely cause dry mouth (1.9%),
thirst, headache (1.2%), nervousness, drowsiness (0.4%), diarrhoea
(0.2%), skin rash & itching (0.1%).
Precautions:
In case of children,
treatment with Apuldon should be continued with caution
because there may be increased risk of extra-pyrimidal reactions
in young children.
Use in pregnancy and Lactation:
The safety of this
drug has not been established for pregnant women. So it is not
recommended during pregnancy. Apuldon may precipitate
galactorrhoea and improve postnatal lactation, which is secreted
in breast milk but in very small quantities insufficient to
be considered harmful.
Drug Interaction:
The hypoprolactinemic
effect of bromocriptine may be reduced by Apuldon. The
effect of antimuscarinics & opioid analgesics may antagonize
Apuldon on GI function.
Packing:
Apuldon Tablet:
Box containing 10x10's tablets in blister pack.
Apuldon Suspension:
Bottle containing 60 ml suspension.
Apuldon Paediatric Drops: Bottle
containing 15 ml drops alongwith a dropper. |
